The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press1810.17650/1818-8338-2013-3-4-93-97PHARMACOTHERAPYФАРМАКОТЕРАПИЯOSTEOARTHROSIS: NEW POSSIBILITIES FOR DELAYED-ACTING SYMPTOM-MODIFYING THERAPYОСТЕОАРТРОЗ – НОВЫЕ ВОЗМОЖНОСТИ СИМПТОМ-МОДИФИЦИРУЮЩЕЙ ТЕРАПИИ ЗАМЕДЛЕННОГО ДЕЙСТВИЯShostakN. A.ШостакН. А.
Russian Federation

Acad. A.I. Nesterov Department of Faculty Therapy

nshostak44@mail.ruPravdyukN. G.ПравдюкН. Г.
Russian Federation

Acad. A.I. Nesterov Department of Faculty Therapy

KlimenkoA. A.КлименкоА. А.
Russian Federation

Acad. A.I. Nesterov Department of Faculty Therapy

KondrashovA. A.КондрашовА. А.
Russian Federation

Acad. A.I. Nesterov Department of Faculty Therapy

ShemenkovaV. S.ШеменковаВ. С.
Russian Federation

Acad. A.I. Nesterov Department of Faculty Therapy

EgorovaV. A.ЕгороваВ. А.
Russian Federation

Acad. A.I. Nesterov Department of Faculty Therapy

N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России1510201373-493971407201414072014Copyright ©; 2013, Shostak N.A., Pravdyuk N.G., Klimenko A.A., Kondrashov A.A., Shemenkova V.S., Egorova V.A.Copyright ©; 2013, Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А., Шеменкова В.С., Егорова В.А.2013Shostak N.A., Pravdyuk N.G., Klimenko A.A., Kondrashov A.A., Shemenkova V.S., Egorova V.A.Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А., Шеменкова В.С., Егорова В.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/18

Objective: to study the efficacy, tolerability, and safety of Artradol in patients with knee osteoarthrosis.

Subjects and methods. The investigation enrolled 35 patients of both sexes, mean age 63,45 ± 6,9 years, with stages II and III gonarthrosisand walking pain intensity > 40 mm visual analog scale. All the patients were given Artradol (chondroitin sulfate) intramuscularly every other day in a dose of 0,1 g (the first 3 injections), its fourth injection was 0,2 g used for 2 months. Changes in the WOMAC index, up-and-go test, as well as the need to use nonsteroidal anti-inflammatory drugs (NSAIDs), and therapeutic efficiency as viewed by the physician and patient were estimated.

Results. The clinical effect of the drug occurred by the average treatment day of 18. Lower needs for NSAIDs were noted in 97 % of the patients;NSAIDs were discontinued in 22 (62 %) cases. There was a statistically significant decrease in the total scores of the WOMAC and up-to-go tests on therapy completion. The therapy resulted in considerable improvement in 97,0 % of the patients.

Conclusion. Artradol has high clinical efficacy and safety and a noticeable delayed-acting symptom-modifying effect, which makes it relevant for use in the treatment of gonarthrosis.

osteoarthrosisgonarthrosisdelayed-acting symptom-modifying effectchondroitin sulfateArtradolостеоартроз, гонартрозсимптом-модифицирующие препараты замедленного действияхондроитин сульфатАртрадол1. Goldring M.B. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000;43(9):1916–26.Goldring M.B. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000;43(9):1916–26.2. Шостак Н.А. Остеоартроз-2013 – новые направления в лечении. Фарматека 2013;7:17–22.Шостак Н.А. Остеоартроз-2013 – новые направления в лечении. Фарматека 2013;7:17–22.3. Zhang W., Doherty M., Leeb B.F. et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of а Тask Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutic (ESCISIT). Ann Rheum Dis 2007;66(3):377–88.Zhang W., Doherty M., Leeb B.F. et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of а Тask Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutic (ESCISIT). Ann Rheum Dis 2007;66(3):377–88.4. Zhang W., Doherty M., Peat G. et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010;69(3):483–9.Zhang W., Doherty M., Peat G. et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010;69(3):483–9.5. Weijer C., Dickens B., Meslin E.M. Bioethics for clinicians: 10. Research ethics. CMAJ 1997;156(8):1153–7.Weijer C., Dickens B., Meslin E.M. Bioethics for clinicians: 10. Research ethics. CMAJ 1997;156(8):1153–7.6. Fransen M., Agaliotis M., Nairn L. et al.; on behalf of the LEGS study collaborative group. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-203954.Fransen M., Agaliotis M., Nairn L. et al.; on behalf of the LEGS study collaborative group. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-203954.7. Morreale P., Manopulo R., Galati M. et al. Comparison of the antiinflammatory efficacy of chondroitinsulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23(8):1385–91.Morreale P., Manopulo R., Galati M. et al. Comparison of the antiinflammatory efficacy of chondroitinsulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23(8):1385–91.8. Аникин С.Г., Алексеева Л.И. Хондроитин сульфат: механизмы действия, эффективность и безопасность при терапии остеоартроза. Совр ревматол 2012;(3): 78–82.Аникин С.Г., Алексеева Л.И. Хондроитин сульфат: механизмы действия, эффективность и безопасность при терапии остеоартроза. Совр ревматол 2012;(3): 78–82.9. Leeb B.F., Schweitzer H., Montag K., Smolen J.S. A metaanalysis of chondroitinsulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205–11.Leeb B.F., Schweitzer H., Montag K., Smolen J.S. A metaanalysis of chondroitinsulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205–11.